Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2023

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2023 – By Drugs Type (Avastin, Tecentriq, Cometriq, Eylea, Other Drug Types), By Route Of Administration (Oral, Intravenous), By Application (Oncology, Ophthalmology, Other Applications) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | Delivery Time: 2-3 business days | Format :

Need assistance or more information before the purchase?

Enquire Before Buying
Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

Proud Members Of

A VEGF inhibitor is an inhibitor that prevents planned cell death by acting as an anti-apoptotic factor for hematopoietic cells. VEGF increases vascular permeability, which may make it easier for tumours to spread via the bloodstream and receive more oxygen and nutrients.

The main types of vascular endothelial growth factor (VEGF) inhibitors are Avastin, Tecentriq, Cometriq, Eylea, and others. Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problems and other retinal issues. It's administered into the eye to help delay the loss of eyesight caused by certain disorders. The different routes of administration include oral, and intravenous and are used in oncology, ophthalmology, and others.

The global vascular endothelial growth factor (VEGF) inhibitor market is segmented -

1) By Drugs Type: Avastin, Tecentriq, Cometriq, Eylea, Other Drug Types

2) By Route Of Administration: Oral, Intravenous

3) By Application: Oncology, Ophthalmology, Other Applications

The global vascular endothelial growth factor (VEGF) inhibitor market size grew from $8.27 billion in 2022 to $8.96 billion in 2023 at a compound annual growth rate (CAGR) of 8.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the vascular endothelial growth factor (vegf) inhibitor is expected to grow from $12.11 billion in 2027 at a CAGR of 7.8%.

The growing prevalence of cancer and macular degeneration diseases is expected to drive the VEGF inhibitor market. For instance, in August 2022, according to this systematic review and meta-analysis published by the National Library of Medicine, a US-based medical library, age-related macular degeneration will affect 8–7% of the global population, with the illness affecting 196 million individuals in 2020 and rising to 288 million by 2040. Anti-vascular endothelial growth factor (anti-VEGF) agents halt the progression of the disease and improve vision. A vascular endothelial growth factor (VEGF) inhibitor slows and restricts tumor growth during cancers. Hence, the rising prevalence of cancer along with macular degeneration disease aids in the vascular endothelial growth factor (VEGF) inhibitor market growth over the forecast period.

Major players in the vascular endothelial growth factor (VEGF) inhibitor market are Pfizer, Amgen, Roche, Xbrane Biopharma AB, Genentech Inc., AstraZeneca PLC., Bayer AG, Eli Lilly and Company and Allergan PLC.

Side effects caused by VEGF inhibitors are expected to hinder the vascular endothelial growth factor (VEGF) inhibitor market. Side effects of treatment with VEGF-targeting angiogenesis inhibitors include hemorrhage and clots in the arteries, which results in a stroke or heart attack, hypertension, reversible posterior leukoencephalopathy syndrome, and impaired wound healing, and protein in the urine. For instance, Bevacizumab, a biosimilar drug approved by FDA, has side effects such as impaired wound healing, hypertension, bleeding, and gastrointestinal perforations. Side effects caused by VEGF inhibitors hinder the VEGF inhibitor market growth.

Key players operating in the VEGF inhibitor industry are undergoing various collaborations and partnerships to expand their product portfolio by developing new products. For instance, in May 2020, AbbVie, a US-based biopharmaceutical company acquired Allergan, Inc., a US-based pharmaceutical company focused on eye care. This acquisition establishes a biopharma firm with leadership roles in vital therapeutic areas such as hematologic oncology, immunology, Allergan Aesthetics, and neuroscience. Furthermore, in January 2020, Exonate, a biotechnology company, collaborated with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson for the development of a new eye drop for the treatment of retinal vascular diseases. Exonerate developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing.

In May 2020, AbbVie Inc., a US-based biopharmaceutical company, acquired Allergan plc for an amount of $63 billion. This acquisition is expected to give AbbVie Inc. an enhanced long-term growth potential along with a growing dividend and investment in innovation in each of Allergan plc’s therapeutic categories. Allergan plc is an Ireland-based pharmaceutical company engaged in the manufacturing of drugs and medical devices in the field of eye care, medical aesthetics, gastroenterology, and the central nervous system.

North America was the largest region in the vascular endothelial growth factor (VEGF) inhibitor market in 2022. Middle East is expected to be the fastest-growing region in the vascular endothelial growth factor (VEGF) inhibitor market share during the forecast period. The regions covered in the global vascular endothelial growth factor (VEGF) inhibitor market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vascular endothelial growth factor (VEGF) inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The vascular endothelial growth factor (VEGF) inhibitor market consists of sales of nexavar, sunitinib, nilotinib, pazopanib, and dasatinib. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The vascular endothelial growth factor (VEGF) inhibitor market research report is one of a series of new reports from The Business Research Company that provides vascular endothelial growth factor (VEGF) inhibitor market statistics, including vascular endothelial growth factor (VEGF) inhibitor industry global market size, regional shares, competitors with a vascular endothelial growth factor (VEGF) inhibitor market share, detailed vascular endothelial growth factor (VEGF) inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the vascular endothelial growth factor (VEGF) inhibitor industry. This vascular endothelial growth factor (VEGF) inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Executive Summary

    2. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Characteristics

    3. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Trends And Strategies

    4. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    4.2 Ukraine-Russia War Impact On Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    4.3 Impact Of High Inflation On Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    5. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Size And Growth

    5.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Segmentation

    6.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Avastin

    Tecentriq

    Cometriq

    Eylea

    Other Drug Types

    6.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By route of administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Oral

    Intravenous

    6.3. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Oncology

    Ophthalmology

    Other Applications

    7. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Regional And Country Analysis

    7.1. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    8.1. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    9.1. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    9.2. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    10.1. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    11.1. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    12.1. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    13.1. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    14.1. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    15.1. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    15.2. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    16.1. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    17.1. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    18.4. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.5. France Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    19.1. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    19.2. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    20.1. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    21.1. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    21.2. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    22.1. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    22.2. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    23.1. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    23.2. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    24.1. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    25.1. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    25.2. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    26.1. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Overview

    26.2. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Landscape And Company Profiles

    27.1. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Competitive Landscape

    27.2. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Company Profiles

    27.2.1. Pfizer

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Amgen

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Roche

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Xbrane Biopharma AB

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Genentech Inc.

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Vascular Endothelial Growth Factor (VEGF) Inhibitor Pipeline Analysis

    29. Key Mergers And Acquisitions In The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market

    30. Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By route of administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: China, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: India, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: India, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: Japan, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: Japan, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: Australia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Australia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Indonesia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Indonesia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: South Korea, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: South Korea, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Western Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Western Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: UK, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: UK, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Germany, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Germany, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: France, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: France, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Eastern Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Eastern Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Russia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Russia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: North America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: North America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: USA, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: USA, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: South America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: South America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: Brazil, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Brazil, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Middle East, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Middle East, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Africa, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Africa, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Pfizer Financial Performance
  • Table 47: Amgen Financial Performance
  • Table 48: Roche Financial Performance
  • Table 49: Xbrane Biopharma AB Financial Performance
  • Table 50: Genentech Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By route of administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: China, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: India, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: India, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: Japan, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: Japan, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: Australia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Australia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Indonesia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Indonesia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: South Korea, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: South Korea, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Western Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Western Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: UK, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: UK, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Germany, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Germany, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: France, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: France, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Eastern Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Eastern Europe, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Russia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Russia, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: North America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: North America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: USA, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: USA, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: South America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: South America, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: Brazil, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Brazil, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Middle East, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Middle East, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Africa, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Drugs Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Africa, Vascular Endothelial Growth Factor (VEGF) Inhibitor Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Pfizer Financial Performance
  • Figure 47: Amgen Financial Performance
  • Figure 48: Roche Financial Performance
  • Figure 49: Xbrane Biopharma AB Financial Performance
  • Figure 50: Genentech Inc. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report